The Economic Information Daily reported on the 12th that Harbin Pharmaceutical (SSE: 600664) announced last night that the company recently received from relevant supervisory commissions the "Notice of Case Filing" and "Notice of Detention" regarding Lu Chuanyou, the company's director and president. The company has made proper arrangements for related duties. The chairman, other directors, and senior management are all performing their duties normally, and the board of directors is operating normally.
Since July this year, Harbin Pharmaceutical's stock price has significantly strengthened, rising from about 3 yuan (RMB, same below) to a peak of 9.86 yuan by the end of September. Harbin Pharmaceutical hit the daily trading limit this morning, closing at 6.65 yuan.
Public information shows that Lu Chuanyou holds a bachelor's degree in chemical pharmacy from Jiamusi Medical College and a master's degree in medicinal chemistry from Shenyang Pharmaceutical University. He previously served as chief engineer, executive deputy plant director, plant director, and Party secretary of the Sixth Pharmaceutical Factory of Harbin Pharmaceutical Group; Party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanchine Pharmaceutical Co., Ltd.; and vice general manager of Harbin Pharmaceutical Group Co., Ltd. Since 2023, he has served as president of Harbin Pharmaceutical Group Co., Ltd., member of the strategic committee, and other positions.
Harbin Pharmaceutical stated that the company has a complete organizational structure and standardized governance system, strictly operating in accordance with relevant regulations. Currently, the company has made proper arrangements for related work. The company's chairman, other directors, and other senior management are all performing their duties normally, the board of directors is operating normally, and business operations are proceeding as usual. The announced matter will not have a significant impact on the company's operational management.
Harbin Pharmaceutical's 2026 interim report shows that in the first half of the year, it achieved operating revenue of 8.296 billion yuan, an increase of 2.10% year-on-year; net profit attributable to shareholders of listed companies reached 410 million yuan, up 57.99% year-on-year; net profit after non-recurring gains and losses attributable to shareholders of listed companies reached 355 million yuan, up 45.39% year-on-year. (jq)
Since July this year, Harbin Pharmaceutical's stock price has significantly strengthened, rising from about 3 yuan (RMB, same below) to a peak of 9.86 yuan by the end of September. Harbin Pharmaceutical hit the daily trading limit this morning, closing at 6.65 yuan.
Public information shows that Lu Chuanyou holds a bachelor's degree in chemical pharmacy from Jiamusi Medical College and a master's degree in medicinal chemistry from Shenyang Pharmaceutical University. He previously served as chief engineer, executive deputy plant director, plant director, and Party secretary of the Sixth Pharmaceutical Factory of Harbin Pharmaceutical Group; Party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanchine Pharmaceutical Co., Ltd.; and vice general manager of Harbin Pharmaceutical Group Co., Ltd. Since 2023, he has served as president of Harbin Pharmaceutical Group Co., Ltd., member of the strategic committee, and other positions.
Harbin Pharmaceutical stated that the company has a complete organizational structure and standardized governance system, strictly operating in accordance with relevant regulations. Currently, the company has made proper arrangements for related work. The company's chairman, other directors, and other senior management are all performing their duties normally, the board of directors is operating normally, and business operations are proceeding as usual. The announced matter will not have a significant impact on the company's operational management.
Harbin Pharmaceutical's 2026 interim report shows that in the first half of the year, it achieved operating revenue of 8.296 billion yuan, an increase of 2.10% year-on-year; net profit attributable to shareholders of listed companies reached 410 million yuan, up 57.99% year-on-year; net profit after non-recurring gains and losses attributable to shareholders of listed companies reached 355 million yuan, up 45.39% year-on-year. (jq)
